Lymphoma highlights from ASCO 2025 include data on CAR-T cell therapy, zilovertamab vedotin in relapsed or refractory (R/R) LBCL, and optimal dosing of AFM13 plus AlloNK in R/R Hodgkin lymphoma.
Dr Flowers first reviews a phase 1 study of KITE-363, an anti-CD19/CD20 chimeric antigen receptor T-cell therapy, in patients with relapsed or refractory . There were no dose-limiting toxicities . Grade 3 adverse events occurred in 76% of patients.
Patients with primary refractory disease had an overall response rate of 80% and a favorable complete response rate of 67%. Dr Flowers also examines the phase 2/3 clinical trial of zilovertamab vedotin plus standard of care in R/R large B-cell lymphoma. The combination showed meaningful efficacy in ORR rates and CR. Dr Flowers next reviews a phase 2 dose-finding study on AFM13 plus cord blood allogeneic NK cells. In 24 heavily pretreated patients who received varying doses of both agents, no dose-limiting toxicity was identified and there were no fatal combinations of adverse events. Efficacy and safety extended across several dosages. The ORR was 88% and the CR was 58%. Finally, Dr Flowers reviews early data on multivirus-specific T cells to enhance bispecific antibodies in lymphoma. The T cells, which were enhanced against EBV, CMV, BK virus, and, demonstrated ability to kill lymphoma cells in vitro, which may prove a future strategy to enhance tumor activity of bispecific antibodies.Any views expressed above are the author's own and do not necessarily reflect the views of WebMD/Medscape or its affiliates.Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our
S Lymphoma Non-Hodgkin Lymphoma NHL Non-Hodgkin Lymphoma (NHL) Lymphoma Malignant Lymphoma Hodgkin Lymphoma Hodgkin Disease Hodgkin' S Lymphoma B-Cell Lymphoma Recap Research Capsule Biologic Therapy Biologics Chimeric Antigen Receptor T-Cell Therapy Chimeric Antigen Receptors Chimeric Immunoreceptors Chimeric T-Cell Receptors Artificial T-Cell Receptors
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
2025 109th Running of the Indianapolis 500 Leaderboard - May 25, 2025View 2025 109th Running of the Indianapolis 500 race, qualifier and practice leaderboards, live streams, bonus cameras, videos and odds information.
Read more »
Seahawks offense 'entirely new' in 2025The 2025 Seahawks will look completely different offensively in 2025.
Read more »
Ambitious, risky, spectacular: We’re lucky to share a city with the Philadelphia orchestraIs the 2025 Philadelphia orchestra the musical equivalent of the 2025 Philadelphia Eagles?
Read more »
Biggest cancer innovations ASCO 2025: exercise as drug, Astra Zeneca early treatmentBusiness Insider tells the global tech, finance, stock market, media, economy, lifestyle, real estate, AI and innovative stories you want to know.
Read more »
Key Highlights in Ovarian Cancer From ASCO 2025Novel drug combinations that improve survival outcomes, questions about treatment sequence, and encouraging results in chemo-resistant disease are highlights in ovarian cancer from ASCO 2025.
Read more »
EGFR+ NSCLC: Experts Weigh Risk vs Reward at ASCO 2025The spotlight was on EGFR+ NSCLC at ASCO 2025, as Drs Olazagasti, Velez, and Velázquez Mañana discuss the latest trial findings.
Read more »